Navigation Links
Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting
Date:4/21/2009

ucts include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. Access recently announced the acquisition of MacroChem Corporation. This acquisition provides Access with three additional late-stage product candidates. Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, has already completed two Phase 3 trials. EcoNail is a topically applied econazole lacquer based on Access' proprietary SEPA polymer technology, for the treatment of onychomycosis, a condition commonly known as nail fungus. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue a
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
2. New organic material may speed Internet access
3. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
4. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
5. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
6. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology
11. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Innovation is more urgent than ever. Radical business ... world and transforming global markets in industry after ... care, disruption is constantly underway. , As technology ... the foundations of established business models, large-scale innovation ... the next wave of mega-change. , This wave ...
(Date:2/26/2015)... , Feb. 26, 2015  Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... financial results for year ending December 31, 2014 ... and will host a conference call that day ...
(Date:2/26/2015)... ANGELES , Feb. 26, 2015 Tauriga ... life sciences company with interests in the natural wellness ... technology, announced today that its products will be featured ... Roth Capital Partners, 27 th Annual Growth Stock ... Carlton, located at 1 Ritz Carlton Drive, ...
(Date:2/26/2015)... Feb. 26, 2015  Spark Therapeutics (NASDAQ: ONCE ... will participate in the Cowen and Company Health Care ... Eastern, at the Boston Marriott Copley Place. ... presentation from the Cowen conference, please visit the "Upcoming ... the Spark Therapeutics website at www.sparktx.com .  A ...
Breaking Biology Technology:One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2
... CUREXO Technology Corporation, pioneer in medical robotics and ... applications, which is focused on marketing its ROBODOC(R) ... relocating its headquarters from Sacramento to Fremont and ... executives; the remainder of the company will be ...
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) ... Term Loan and Revolving Credit Facility. Wells Fargo Foothill, ... for both the Term Loan and Revolving Credit Facility. ... loan facility of up to $10 million, and a ...
... the UK biotechnology and research services company announced ... collaboration with Novartis,to identify new drug targets and ... The collaboration combines Epistem,s stem ... into disease pathways &,bioinformatics. , ...
Cached Biology Technology:CUREXO Technology Corporation Announces New Headquarters 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4Epistem Announces Research and Development Collaboration With a Major Pharmaceutical Company 2
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... Conn. , Jan. 28, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... at the upcoming RedChip Global Online CEO Conference on ... Gino Pereira , CEO of NXT-ID ... its lead product, the Wocket smart wallet and its ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... Ariz. April 6, 2010 Scottsdale-based TGen Drug ... (GPEC) this week at BayBio2010 in an effort to ... conference April 7 in San Francisco sponsored by BayBio, ... bioscience companies, more than any other single region in ...
... study reconstructing thousands of years of fire history in the ... burns, as a tool to reduce the risk of wildfires, ... in the region,s forests. Duke University researchers used ... to more than 4,000 years ago to reconstruct the fire ...
... from the University of Cordoba (UCO) has analysed seroprevalence ... the parasite that causes toxoplasmosis in many species, including ... widespread in areas where the wild Iberian Lynx ( ... centres. Scientists are now undertaking further research into the ...
Cached Biology News:TGen Drug Development accompanies GPEC to BayBio2010 24,000-year study supports use of prescribed burns in Southern Appalachians 24,000-year study supports use of prescribed burns in Southern Appalachians 3Toxoplasma gondii spreads in the habitat of the Iberian lynx 2
... Exiqons LNA technology enables sensitive, fast ... on intact chromosomes. Short hybridisation ... fixed cells and chromosome spreads Multiplex ... Pre-validated probes Probes available ...
... Bacterial DNA Isolation Kit provides a rapid ... genomic DNA from the various bacterial species ... the isolation of genomic DNA from both ... milk samples. ,Purification is based on ...
... (Intein Mediated Purification with an Affinity Chitin-binding ... engineered protein splicing elements (termed inteins) to ... column (1-4) (Figures 1 and 2). This ... systems by its ability to separate a ...
... CHEMICON's Skeletal Myogenesis Kit provides the ... myoblasts into mature skeletal myotubes. By ... is a valuable tool in studies ... in developing strategies for muscle cell ...
Biology Products: